Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectafer vs Oral Iron in IDA Secondary to IBD or Gastric Bypass
NCT02086968Phase 4Completed
- Sponsor
- American Regent, Inc.
- Start
- Jan 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by American Regent, Inc. Primary endpoint: Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders) at Day 28. Started Jan 2014; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02086968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086968.